Neurotensin Peptide Research: NTS1/NTS2 Receptor Pharmacology, Dopaminergic Circuit Modulation, and Preclinical Evidence

Neurotensin is a tridecapeptide, pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu, acting at two G protein-coupled receptors, NTS1 and NTS2, and at sortilin, and neurotensin peptide research is organised around a single pharmacological problem: the receptor that produces most of the interesting central effects also produces hypothermia and hypotension. Separating those has driven the chemistry of the field for two decades, and the current answer is NTS2-selective analogues. The C-terminal hexapeptide NT(8-13) retains full receptor activity, which makes it the standard scaffold. Neurotensin is a reference compound discussed here for its pharmacology; it is not an item in the Maple Research Labs catalogue.

Disclaimer: For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. The information presented here is drawn from published scientific literature and is intended solely for educational reference.

Structure and Receptors

Carraway and Leeman isolated the peptide from bovine hypothalamus and published the amino acid sequence in the Journal of Biological Chemistry (1975, 250:1907-1911, PMID 1167549); the intestinal form was sequenced separately (Journal of Biological Chemistry 1978, 253:7996-7998, PMID 711731, and for human intestine 1980, 255:2476-2480, PMID 7358684). The molecular formula is C78H121N21O20 with an average mass of 1672.9 Da. For mass spectrometric identity work the doubly protonated ion sits at approximately m/z 837.5 rather than the 836.9 given in an earlier version of this page, a small difference that matters when it is being used as an acceptance criterion.

Three receptors are recognised. NTS1 is a class A G protein-coupled receptor coupling through Gq with phospholipase C activation. NTS2 has a distinct pharmacology, notably its affinity for the antihistamine levocabastine, which is the practical basis for distinguishing the two in binding assays. NTS3 is sortilin, a single-transmembrane protein structurally unrelated to the other two and functioning largely in intracellular trafficking. Structural work on NTS1 began with the agonist-bound crystal structure (Nature 2012, 490:508-513, PMID 23051748), which followed the thermostabilisation work that made it tractable (Journal of Molecular Biology 2009, 390:262-277, PMID 19422831), and continued with the constitutively active receptor (Scientific Reports 2016, 6:38564, PMID 27924846). An earlier version of this page attributed cryo-EM structures to Kato in 2016; the primary structural citation for the agonist-bound receptor is the 2012 Nature paper.

The Hypothermia and Analgesia Problem

Central neurotensin produces naloxone-insensitive antinociception, and it produces hypothermia, and for a long time nobody could reliably separate them. Both NTS1 and NTS2 mediate analgesic effects, while NTS1 activation additionally produces hypotension and hypothermia. That is the constraint the medicinal chemistry has been working against, and it is the reason hypothermia became a convenient in vivo readout of NTS1 engagement.

The receptor assignment on the analgesia side came from spinal work. In the formalin model (Molecular Pain 2009, 5:38, PMID 19580660), spinally administered neurotensin and the mixed NTS1/NTS2 agonist NT69L reduced pain-evoked responses during the inflammatory phase, and the NTS2-selective compounds JMV-431 and levocabastine inhibited formalin-induced aversive behaviours and reduced formalin-induced c-fos expression in dorsal horn neurons. The informative detail is the dissociation rather than the magnitude: non-selective compounds suppressed behaviour across both the early and late parts of phase 2, while intrathecal NTS2-selective agonists reduced pain only during late phase 2, and where non-selective analogues reversed all the stereotypic endpoints, pure NTS2 agonists specifically inhibited paw lifting. That pattern argues the two receptors recruit inhibitory mechanisms integrated at different levels of the neuraxis. An earlier version of this page attributed a 47 percent reduction in phase II flinching to a 2014 Pain paper by Xiao that could not be located.

The problem now has a chemical solution worth knowing about. A series of NT(8-13) analogues carrying a reduced amide bond at Lys8-Lys9 with silaproline at position 10 and trimethylsilylalanine at position 13 (Behavioural Brain Research 2021, 405:113189, PMID 33607165) produced JMV5296, with a plasma half-life beyond twenty hours and twenty-five-fold selectivity for NTS2. Centrally delivered, it produced strong antinociception in acute tail-flick, tonic formalin and chronic CFA inflammatory models without inducing hypothermia. NTS2 involvement in stress-induced analgesia has been characterised separately (Neuroscience 2010, 166:639-652, PMID 20035838), and the role of NTS2 in tolerance to the mixed agonist NT69L across hypothermia and thermal analgesia endpoints is described in Behavioural Brain Research (2011, 224:344-349, PMID 21718721). An earlier version of this page attributed the knockout thermoregulation conclusion to a 2014 Jung study that could not be located.

SR 48692, the first selective non-peptide NTS1 antagonist, was characterised by Gully and colleagues in the Proceedings of the National Academy of Sciences (1993, 90:65-69, PMID 8380498) and remains the standard pharmacological tool for assigning an effect to NTS1. Its signalling profile was mapped in more detail subsequently (British Journal of Pharmacology 1995, 116:1899-1905, PMID 8528577).

Dopaminergic Circuit Modulation

The interaction with mesolimbic and nigrostriatal dopamine pathways is the oldest sustained research thread on this peptide and the origin of the description of neurotensin as an endogenous antipsychotic, based on the observation that central administration produces hypothermia and catalepsy resembling haloperidol. The hypothesis has been reviewed at length (Biological Psychiatry 2001, 50:856-872, PMID 11743941; Seminars in Clinical Neuropsychiatry 2003, 8:94-108, PMID 12728409; International Review of Neurobiology 2007, 78:327-376, PMID 17349866), and those reviews are the appropriate citation for the framework rather than the specific microdialysis percentages, group sizes and DOPAC to dopamine ratios that appeared in an earlier version of this page attributed to Ferraro in 2008 and Binder in 2001, none of which could be traced to a located source.

The human clinical-correlate literature is real but modest. Cerebrospinal fluid neurotensin concentrations in schizophrenia and their relationship to antipsychotic treatment were examined in the American Journal of Psychiatry (1997, 154:1019-1021, PMID 9210757) and in Schizophrenia Research (1994, 12:35-41, PMID 7517175). These are correlational measurements in small samples, and they are the basis for interest in the system rather than evidence of a causal deficit.

On the preclinical side the useful tool compounds are the brain-penetrant analogues, since native neurotensin does not cross the blood-brain barrier in useful quantity. NT69L blocked phencyclidine-induced increases in locomotor activity (Brain Research 2010, 1311:28-36, PMID 19948149), and chronic administration prevented drug-induced disruption of prepulse inhibition without producing tolerance (Behavioural Brain Research 2010, 207:118-124, PMID 19800922), the latter being the more interesting result because tolerance is where most candidates in this class have failed. Receptor attribution for the behavioural effects of NT-69L and a second agonist was addressed directly in European Neuropsychopharmacology (2009, 19:466-475, PMID 19223157), and sensorimotor gating was compared across NTS1 and NTS2 null mice in the Journal of Experimental Biology (2010, 213:4232-4239, PMID 21113004). A 73 percent reduction in methamphetamine-induced locomotion attributed on this page to a 2010 Feifel paper could not be located and has been removed.

Peripheral Neurotensin and Fat Absorption

The metabolic result is the most consequential recent finding in this literature, and an earlier version of this page cited it to the wrong journal and the wrong genotype. It is Li and colleagues in Nature (2016, 533:411-415, PMID 27193687), not Cell, and the mice are neurotensin-deficient rather than NTS1-null. Those mice showed significantly reduced intestinal fat absorption and were protected from obesity, hepatic steatosis and insulin resistance on high fat consumption. The mechanism reported is that neurotensin attenuates activation of AMP-activated protein kinase and stimulates fatty acid absorption in mice and in cultured intestinal cells, through NTR1 and NTR3 (sortilin) rather than NTR1 alone, which is one of the few clear functional roles established for the sortilin arm.

The study also crossed species and into humans. Expressing neurotensin in Drosophila midgut enteroendocrine cells increased lipid accumulation in midgut, fat body and oenocytes with decreased AMPK activation. In humans, obese and insulin-resistant subjects had elevated plasma pro-neurotensin, the stable precursor fragment produced in equimolar amounts with the peptide, and in longitudinal follow-up of non-obese subjects high pro-neurotensin was associated with a doubling of the risk of developing obesity later. The fat mass percentages and postprandial triglyceride values previously given on this page are not in that paper and have been removed.

Neurotensin is released from intestinal enteroendocrine cells in response to fat ingestion, which is the physiological context for all of the above. Researchers comparing gut peptide mechanisms may find the GLP-2 and teduglutide intestinal research summary a useful contrast, since that peptide is trophic to the epithelium where this one modulates absorption across it.

Stability and Handling

Native neurotensin is degraded rapidly in plasma and brain tissue, which is why most in vivo work uses central administration or a stabilised analogue. The principal cleavage sites reported in the literature are within the C-terminal region that carries the receptor-active pharmacophore, which is why degradation abolishes activity rather than merely reducing it, and why the NT(8-13) analogues above concentrate their modifications there. An earlier version of this page assigned specific cleavage positions to named enzymes without a source and gave a sub-thirty-second systemic half-life; both have been removed in favour of the qualitative statement, which is what the primary literature supports without a dedicated pharmacokinetic citation.

For in vitro work, stock solutions are normally prepared in sterile water or dilute acetic acid, aliquoted and stored frozen to avoid repeated freeze-thaw cycling, with protease inhibitors included in cell-based incubations. The purity question that matters specifically for this peptide is truncation: because NT(8-13) is itself fully active and NT(1-8) is not, a preparation contaminated with C-terminal fragments will show activity that does not correspond to the nominal compound, and a preparation contaminated with N-terminal fragments will underperform its stated concentration. Neither is visible without a chromatographic separation that resolves them. General methodology is set out in the discussion of HPLC testing for peptide purity and in the treatment of mass spectrometry for identity confirmation.

Where a batch of a compound in our catalogue has been tested, the independent laboratory report is published on the certificates of analysis page, which also lists the compounds still awaiting a report. Neurotensin is not a catalogue compound, and an earlier version of this page stated that batch certificates accompanied it. The research peptide catalogue and the documentation section cover the compounds that are stocked.

Related Peptide Systems

Substance P and NK1 receptor pharmacology covers the other well-characterised peptide input to dorsal horn nociceptive processing, with the opposite sign: substance P is pro-nociceptive where neurotensin is inhibitory. For peptide modulation of central innate immune signalling, the cortistatin research summary sets out a separate receptor system. Neuropeptide modulation of ventral tegmental dopamine neurons is also discussed in the oxytocin receptor pharmacology summary.

Citations in this article were checked against the indexed PubMed record on 20 September 2026. Corrections made in this revision: the journal and mouse genotype for the 2016 obesity study, the structural biology attribution, the doubly protonated ion mass, and the replacement of untraceable citations attributed to Ferraro 2008, Binder 2001, Clineschmidt and McGuffin 1977, Xiao 2014, Jung 2014, Feifel 2010 and Lepinay 2019 with primary studies that report the underlying findings.

Neighbouring neuropeptide systems are reviewed in the substance P and NK1 receptor article, the neuropeptide S NPSR1 research review and the galanin receptor research summary.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.